1319 SIMTUZUMAB, AN ANTIFIBROTIC MONOCLONAL ANTIBODY AGAINST LYSYL OXIDASE-LIKE 2 (LOXL2) ENZYME, APPEARS SAFE AND WELL TOLERATED IN PATIENTS WITH LIVER DISEASE OF DIVERSE ETIOLOGY
1319 SIMTUZUMAB, AN ANTIFIBROTIC MONOCLONAL ANTIBODY AGAINST LYSYL OXIDASE-LIKE 2 (LOXL2) ENZYME, APPEARS SAFE AND WELL TOLERATED IN PATIENTS WITH LIVER DISEASE OF DIVERSE ETIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started